Zurcher Kantonalbank (Zurich Cantonalbank) Bio Xcel Therapeutics, Inc. Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $34.1 Billion
- Q4 2024
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 1,653 shares of BTAI stock, worth $2,859. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,653
Previous 6,028
72.58%
Holding current value
$2,859
Previous $3,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding BTAI
# of Institutions
52Shares Held
8.63MCall Options Held
34.5KPut Options Held
59.4K-
Armistice Capital, LLC New York, NY4.32MShares$7.46 Million0.02% of portfolio
-
Ubs Group Ag1.28MShares$2.21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.19MShares$2.05 Million0.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$762,3850.0% of portfolio
-
Geode Capital Management, LLC Boston, MA312KShares$539,6990.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $48.5M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...